Dublin, January 12, 2021 (GLOBE NEWSWIRE) – Added to the report “non-small cell lung cancer – global drug forecast and market analysis to 2029” ResearchAndMarkets.com’s offering.
Non-small cell lung cancer (NSCLC) is currently the most common cancer in the world and is the leading cause of cancer mortality in both men and women. Of the total lung cancer incidence cases, about 85% are as the NSCLC subtype. NSCLC patients are usually found in the late stages of the disease, leading to a poor prognosis. Since the last forecast on the global market (2015-2025), there have been significant changes in the treatment of patients with advanced disease, especially in the metastatic condition.
Although NSCLC is not considered treatable, physicians are committed to the progress being made in this area. New producers provide more sustainable responses, as evidenced by improvements in non-progressive survival and overall survival. Progress has been demonstrated by the introduction of check protectors into the first-line and targeted generation therapy of the next generation which has significantly improved patient outcomes.
These recent successes will be built upon in the forecast period. Personalized medicine is becoming more sophisticated, with the development of agents focusing on molecular disorders, which are currently under the protection of available therapies. In addition, new producers will allow them to focus on new action mutations. The strategic use of these targeted agents and immuno-oncology (IO) -based therapies in effective combinatorial regimens in the neoadjuvant and adjuvant settings for treatment-specific treatment population numbers is expected to change over the expected period .
The publisher expects 29 new entrants to be introduced over the projected period of 2019-2029. In this report, the publisher has emphasized the clinical and commercial potential of each NSCLC treatment to predict market growth and identify new commercial opportunities.
Key questions answered
- 29 late pipeline manufacturers are entering the NSCLC market from 2019 onwards. Will these producers have an impact on the market? Which of these drugs has the highest sales, and why?
- What are the current unmet needs in NSCLC, what pipe representatives are in a position to address the unmet needs? What are the opportunities for R&D?
- What is the market outlook for the 8MM from 2019-2029? Considering major patented finishes, the launch of new high-priced manufacturers and the expected expansion of labels.
- What are the main physical movements? Who are the current and future players?
Key events
- The key growth drivers include the approval and expectation of 29 pipeline therapies, as well as the label expansion of therapies currently marketed over the 8MM over the expected period.
- The main barriers to growth in the 8MM include patent termination of major brands and high therapeutic price at a high price entering the market.
- Among the late pipeline products and market representatives, Checkpoint defenders and EGFR defenders are expected to generate the most revenue over the expected period.
- The most important unmet needs in the NSCLC market include: Complete molecular testing, innovative approaches to primary and acquired primary stress and development in therapeutic options
Scope
- Overview of NSCLC including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment management.
- NSCLC Topline market revenue, annual treatment cost, and key pipeline product sales in the forecast period.
- Key topics include routine treatment and pipeline treatments, unmet needs and opportunities, and the drivers and barriers affecting NSCLC therapeutic sales in the 8MM.
- Pipeline analysis: Complete data divided across different phases, emerging novel trends under development, and detailed analysis of late pipeline drugs (Phase III).
- Analysis of current and future market competition in NSCLC global market. A visual review of the industry’s key directions, constraints and challenges. Each movement is independently analyzed to provide a qualitative analysis of its impact.
Reasons to buy
- Develop and design your inbound and outsourcing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the strongest pipelines.
- Develop business strategies by understanding the trends shaping and driving the global NSCLC medicine market.
- Manage revenue by understanding key trends, innovative products and technologies, market segments, and companies that are likely to impact the future NSCLC global market.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of different competitors.
- Identify emerging players with potentially strong product charts and create effective strategies to gain competitive advantage.
- Monitor drug sales in the global NSCLC pharmaceutical market from 2019-2029.
- Organize your sales and marketing efforts by identifying market segments and segments that offer the greatest opportunities for consolidation, investments and strategic partnerships.
Key topics covered:
1 Contents
1.1 List of records
1.2 List of Figures
2 NSCLC: Executive Summary
2.1 The NSCLC Market will expand to $ 32.9B in 2029
2.2 Targeting large numbers of patients in the first line, with a focus on establishing New Applied Modifications and Extending Label for Premium Products into earlier lines
2.3 Remaining opportunities to challenge primary and beneficial support for targeted and IO-based treatments
2.4 First-class agreements for modern novel moves and focus on stance
2.5 What do doctors think?
3 Introduction
3.1 Catalyst
3.2 Related reports
3.3 Forthcoming reports
4 Overview of disease
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or stage systems
5 Epidemiology
5.1 Disease Background
5.2 Risk factors and comorbidities
5.3 Global and Historical Trends
5.4 Prediction approach
5.4.1 Sources used
5.4.2 Opinions and Methods Preview
5.4.3 Diagnosis Incident Issues of NSCLC
5.4.4 Diagnosis Incident Incidents of NSCLC by Diagnosis stage
5.4.5 Incident Diagnosis Cases of NSCLC by History Types
5.4.6 Stones among confirmed cases of non-squamous cell carcinoma and squamous cell carcinoma
5.4.7 Five Year Diagnosis Common NSCLC
5.5 Epidemiological Forecast for NSCLC, 2019-2029
5.5.1 Diagnosis Incident Issues of NSCLC
5.5.2 Diagnosis Incident Issues A specific feature of NSCLC
5.5.3 NSCLC Age Specific Diagnosis Incident Incidents
5.5.4 Diagnosis Incident Incidents of NSCLC by Diagnosis stage
5.5.5 Incident Issues Diagnosis of NSCLC by type of history
5.5.6 Confirmed incidence of non-squamous cell carcinoma with mutations: Genomic biomarkers, EGFR and KRAS Mutations
5.5.7 Proven incidence cases of squamous cell carcinoma with variants
5.5.8 Five Year Diagnosis Common NSCLC
5.6 Conversation
5.6.1 Epidemiological prognosis opinion
5.6.2 Impact of COVID-19
5.6.3 Limitations of the study
5.6.4 Strengths of the study
6 Disease control
6.1 Diagnosis and Treatment Review
6.2 US
6.3 5EU
6.4 Japan
6.5 China
7 Competitive Assessment
7.1 Preview
8 Unmet Needs and Fair Assessment
8.1 Preview
8.2 Further Education, Application and Analysis of Comprehensive Molecular Tests
8.3 Opposing primary and access to immunity
8.4 Personalized procedures for dealing with opposition
8.5 Development of therapeutic options and patient outcomes for those without functional transitions
9 Pipe Assessment
9.1 Preview
9.2 Commitment to drugs in clinical development
10. Current and upcoming players
10.1 Preview
10.2 Trends in Corporate Strategy
10.3 Merck & Co.
10.4 AstraZeneca
10.5 Roche
10.6 Eli Lilly
10.7 BMS
10.8 Pfizer
10.9 Boehringer Ingelheim
10.10 Novartis
10.11 Future Players
11. Market forecast
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers – Global Issues
11.2 5EU
11.2.1 Estimate
11.2.2 Key events
11.2.3 Drivers and Obstacles
11.3 Japan
11.4 US
11.5 China
For more information on this report, visit https://www.researchandmarkets.com/r/wgp6d7
Research and Markets also offers Custom Search services providing targeted, complete and unique search.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900